Evidence map›Paper›PMID 35416404›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

The small HDL particle hypothesis of Alzheimer's disease.

Ashley E Martinez, Gali Weissberger, Zsuzsanna Kuklenyik, Xulei He, Cristiana Meuret, Trusha Parekh, Jon C Rees, Bryan A Parks, Michael S Gardner, Sarah M King and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Immune-proteo-metabolomic changes link to Aβ and tau pathology in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Ashley E MartinezDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Gali WeissbergerThe Interdisciplinary Department of Social Sciences, Bar Ilan University, Israel.
Zsuzsanna KuklenyikClinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Xulei HeDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Cristiana MeuretDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Trusha ParekhDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Jon C ReesClinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bryan A ParksClinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michael S GardnerClinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sarah M KingDepartments of Pediatrics and Medicine, University of California, San Francisco, California, USA.
Timothy S CollierQuest Diagnostics, Cleveland HeartLab, Cleveland, Ohio, USA.
Michael G HarringtonDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Melanie D SweeneyDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA.
Xinhui WangDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Berislav V ZlokovicDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA.
Elizabeth JoeDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Daniel A NationIrvine, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.
Lon S SchneiderDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
Helena C ChuiDepartment of Neurology, University of Southern California, Los Angeles, California, USA.
John R BarrClinical Chemistry Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
S Duke HanDepartment of Family Medicine, University of Southern California, Los Angeles, California, USA.
Ronald M KraussDepartments of Pediatrics and Medicine, University of California, San Francisco, California, USA.
Hussein N YassineDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
University of Southern California · USCenters for Disease Control and Prevention · USUniversity of California, San Francisco · USBar-Ilan University · ILCleveland BioLabs (United States) · USUniversity of California, Irvine · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARTHUR W TOGA · 2016 to 2026
$28.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Pharmacogenomics of Statin TherapyP50GM115318 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RISCH, NEIL J. · 2015 to 2019
$14.0M
RESEARCH TRAINING IN GERONTOLOGYT32AG000037 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JENNIFER A AILSHIRE, EILEEN M CRIMMINS · 1985 to 2026
$13.2M
Revision Supplement: Model-based cerebrovascular markers extracted from hemodynamic data for diagnosing MCI or AD and predicting disease progressionR01AG058162 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BILLINGER, SANDRA A, CHUI, HELENA CHANG · 2018 to 2022
$11.5M
Alzheimer's Abeta, Tau, Apolipoproteins and Blood-brain barrierR01NS034467 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 1995 to 2024
$9.1M
The delivery of essential fatty acids to the Brain in Alzheimer's diseaseR01AG054434 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$5.4M
Asian Cohort for Alzheimer's Disease (ACAD)R56AG069130 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CHUI, HELENA CHANG, JUN, GYUNGAH · 2020 to 2021
$4.9M
Biomarkers of ABCA1 mediated functions in Alzheimers diseaseR01AG055770 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2017 to 2021
$4.2M
Alzheimer's Disease & Related Dementias: Geography, Environments, and MechanismsRF1AG054068 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, JIU-CHIUAN · 2016 to 2016
$4.1M
ApoE, ABCA1 and endosomal dysregulation in ADR01AG067063 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YASSINE, HUSSEIN N · 2020 to 2024
$3.4M
NIA NIH HHS P01 AG052350NIA NIH HHS P30 AG066530NIA NIH HHS P50 AG005142NIA NIH HHS R01 AG023084NIA NIH HHS R01 AG033078NIA NIH HHS R01 AG039452NIA NIH HHS R01 AG054434NIA NIH HHS R01 AG055430NIA NIH HHS R01 AG055770NIA NIH HHS R01 AG058162NIA NIH HHS R01 AG067063NIA NIH HHS R01 AG072490NIA NIH HHS R21 AG056518NIA NIH HHS R56 AG069130NIA NIH HHS RF1 AG054068NIA NIH HHS RF1 AG068166NIA NIH HHS RF1 AG072490NIA NIH HHS RF1 AG076124NIA NIH HHS T32 AG000037NIEHS NIH HHS R01 ES025888NIGMS NIH HHS P50 GM115318NINDS NIH HHS R01 NS034467
6 · The paper itself

Abstract

We propose the hypothesis that small high-density lipoprotein (HDL) particles reduce the risk of Alzheimer's disease (AD) by virtue of their capacity to exchange lipids, affecting neuronal membrane composition and vascular and synaptic functions. Concentrations of small HDLs in cerebrospinal fluid (CSF) and plasma were measured in 180 individuals ≥60 years of age using ion mobility methodology. Small HDL concentrations in CSF were positively associated with performance in three domains of cognitive function independent of apolipoprotein E (APOE) ε4 status, age, sex, and years of education. Moreover, there was a significant correlation between levels of small HDLs in CSF and plasma. Further studies will be aimed at determining whether specific components of small HDL exchange across the blood, brain, and CSF barriers, and developing approaches to exploit small HDLs for therapeutic purposes.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBrainCognitionHumansAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EAPOEcerebrospinal fluidcognitionHDLlipidomicsproteomics

Identifiers

PMID35416404
PMCPMC10563117
OpenAlexW4223573151

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.